Tags:BioTechDevelopmentDiagnosticsPersonalResearchTechnologyToolsUniversity
PreludeDx was founded to deliver actionable tools to manage early stage breast cancer. PreludeDx's first diagnostic test, DCISionRT is the result of over a decade of research and development focused on DCIS. PreludeDx began developing its DCIS test in 2009 after licensing technology from University of California, San Francisco. DCISionRT’s technology was designed from the beginning to address the critical question faced by patients with DCIS. What is my risk of recurrence and what treatment is appropriate?
Likes
84
Location: United States, California, Laguna Hills
Member count: 11-50
Phone: 1.888.211
Total raised: $20M
Founded date: 2009

Investors 2

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
22.03.2022-$20M--

Mentions in press and media 9

DateTitleDescriptionCategoryAuthorSource
31.10.2022GenesisCar...CALIFORNIA CITY, Calif., Oct. ...--en.prnasia...
02.02.2022PreludeDx™...LAGUNA HILLS, Calif., Feb. 2, ...--marketscre...
29.09.2021PreludeDx ...LAGUNA HILLS, Calif., Sept. 29...--marketscre...
04.06.2021DCISionRT ... LAGUNA HILLS, Calif., June 4...--prnewswire...
04.03.2021DCISionRT®... LAGUNA HILLS, Calif., March ...--prnewswire...
08.12.2020DCISionRT®... LAGUNA HILLS, Calif., Dec. 8...--prnewswire...
24.11.2020PreludeDx™... LAGUNA HILLS, Calif., Nov. 2...--prnewswire...
-DCISionRT®...LAGUNA HILLS, Calif., March 4,...--oaoa.com/n...
-Fourth Val...LAGUNA HILLS, Calif., March 18...--oaoa.com/n...